Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010

Abstract

Background The incidence of rare cutaneous malignancies is unknown. Current estimates of rare cutaneous malignancy incidences are based on broad epidemiologic data or single institution experiences, not population-based data. Objective To determine the incidence of several rare non-melanoma skin cancers. Methods & Materials We conducted a retrospective chart review of a population-based cohort between the years 2000 and 2010. Residents of Olmsted County, Minnesota, who were diagnosed with a biopsy-proven non-melanoma skin cancer - excluding basal cell carcinoma and squamous cell carcinoma - were included in this study. The primary outcome was tumor incidence. Additionally, we extracted patient demographics, tumor characteristics, treatment modalities, and outcomes. Results The age- and sex-adjusted incidences per 100,000 persons of multiple rare cutaneous malignancies were: atypical fibroxanthoma (1.8), sebaceous carcinoma (0.8), dermatofibrosarcoma protuberans (0.4), microcystic adnexal carcinoma (0.7), eccrine carcinoma (0.4), eccrine porocarcinoma (0.2), and leiomyosarcoma (0.2). Conclusion We report population-based incidences and clinical characteristics for these rare cutaneous malignancies. The immune status and smoking status of patients and the treatment and outcomes of these tumors are reported. Additional studies in a broader population are needed to further define the epidemiology and outcomes of these malignancies.

Trends in the incidence and survival of eccrine malignancies in the United States: A SEER population-based study

“…To the Editor: Eccrine malignancies are rare cutaneous tumors that are incompletely described on a population level. 1 In addition, little information exists regarding differences in the clinical characteristics of eccrine malignancies among different demographic groups. 2 The objective of this study is to elucidate trends in the incidence, clinical characteristics, and mortality of primary eccrine malignancies using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) 18 registries from 2000 to 2013.…”

“…To the Editor: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas; therefore, clinicopathologic features of this subtype are not well established. 1,2 It is important to differentiate cases of systemic PTCL-NOS from primary cutaneous PTCL-NOS because the prognosis varies depending on the primary tumor site. 3,4 We analyzed the clinicopathologic characteristics according to the primary tumor site by comparing primary with secondary cutaneous PTCL-NOS.…”

Radioterapia en porocarcinoma ecrino: revisión de la literatura

“…Cuenta con una incidencia de 0.2 por cada millón de habitantes y de 0.005% dentro de los tumores epiteliales 2,3 . A pesar de haber reportes descritos en pacientes desde los 37 años, es más común en adultos mayores de 70 años de edad y corresponde en el 70% de los casos a mujeres, como el caso que presentamos 6,7 .…”

“…También se puede rea- lizar con antígeno carcinoembrionario, la anticitoqueratina 5.2 y la citoqueratina 19, la cual es útil para su diferenciación del carcinoma escamocelular. En el caso de la tinción con S100, ésta delinea los ductos en el porocarcinoma ecrino y tiñe las células mioepiteliales de las porciones glandulares, mientras que las hendiduras de éste son negativas 3,8 . El porocarcinoma ecrino cuenta con una escueta descripción de sus factores pronósticos.…”

“…Esta enfermedad también es conocida como hidroacantoma maligno simple, poroma displásico, siringoacantoma maligno o poroma ecrino intraepidérmico maligno, entre otros términos 1 . Fue descrita por Pinkus y Mehran en el tobillo de una mujer de 82 años en 1963, y hay un número muy reducido de reportes alrededor del mundo desde entonces 2,3 . Su incidencia es ligeramente mayor en el sexo femenino, localizándose el 40% en miembros inferiores y el 20% en la región de cabeza y cuello 4 .…”